Ralmitaront - Roche
Alternative Names: NTX-2001; RG-7906; RO-6889450Latest Information Update: 28 Feb 2025
At a glance
- Originator Roche
- Developer Chugai Pharmaceutical; Roche
- Class Antipsychotics; Behavioural disorder therapies; Morpholines; Pyrazoles; Small molecules
- Mechanism of Action Trace amine-associated receptor 1 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Psychiatric disorders
- Discontinued Schizoaffective disorder; Schizophrenia
Most Recent Events
- 28 Feb 2025 No recent reports of development identified for phase-I development in Psychiatric-disorders(Combination therapy, In volunteers) in USA (PO, Capsule)
- 28 Feb 2025 No recent reports of development identified for phase-I development in Psychiatric-disorders(In volunteers) in Japan (PO, Capsule)
- 28 Feb 2025 No recent reports of development identified for phase-I development in Psychiatric-disorders(In volunteers) in Netherlands (PO, Capsule)